ArticleFrontiers in endocrinology2026
The nomogram prediction model for primary aldosteronism: the combination of serum and urine electrolytes and serum uric acid.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To construct and preliminarily validate a novel nomogram for primary aldosteronism (PA) risk estimation, with the goal of providing a potential reference tool for PA screening in clinical practice. Methods: Hypertensive inpatients who underwent PA screening at the Department of Endocrinology and Metabolism, Cardiology, and Urology of Tianjin Medical University General Hospital from October 2021 to July 2024 were included. Basic information and laboratory test results of the patients were collected, and were randomly divided into training set and validation set at a 7:3 ratio. Differential analysis, Lasso regression, univariate logistic regression, and multivariate logistic regression were used to screen the variables associated with PA. The model results were presented as a nomogram. Predictive ability was assessed by plotting receiver operating characteristic (ROC) curves, and the diagnostic performance of the model was compared using the DeLong test. The Hosmer-Lemeshow test was used to evaluate the goodness of fit of the regression model. The clinical utility of the model was evaluated by clinical decision curve analysis (DCA). Results: Six indicators including serum sodium-to-potassium ratio, anion gap, uric acid, urine sodium, 24-hour urine potassium and urine pH were used to construct a nomogram prediction model for PA. The training and validation sets achieved area under the curve (AUC) values of 0.860 (95% CI: 0.825-0.894) and 0.850 (95% CI: 0.800-0.899), respectively. The AUCs of the validation set for PFK score and ARR were 0.718 (95% CI: 0.656-0.781) and 0.965 (95% CI: 0.943-0.987), respectively. The model demonstrated good discrimination ability. The Hosmer-Lemeshow test indicated a good fit (training set: Conclusion: The nomogram model based on serum sodium-to-potassium ratio, anion gap, uric acid, urine sodium, 24-hour urine potassium and urine pH can predict the risk of PA, facilitating PA screening in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.